Loading...
XNAS
DERM
Market cap182mUSD
Dec 05, Last price  
7.93USD
1D
1.54%
1Q
13.12%
IPO
-11.89%
Name

Journey Medical Corp

Chart & Performance

D1W1MN
XNAS:DERM chart
P/E
P/S
3.26
EPS
Div Yield, %
Shrs. gr., 5y
4.17%
Rev. gr., 5y
9.96%
Revenues
56m
-29.11%
7,300,0007,300,00022,585,0004,541,00042,339,00034,921,00044,531,00063,134,00073,669,00079,181,00056,134,000
Net income
-15m
L+280.79%
-31,875,000-78,399,000-89,084,000-303,261,000-221,540,0003,625,0005,283,000-43,994,000-29,628,000-3,853,000-14,672,000
CFO
-9m
L
-31,404,000-48,442,000-74,111,000-103,963,000-213,098,0009,018,0005,132,000-2,181,000-13,534,0005,240,000-9,127,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
IPO date
Nov 12, 2021
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT